• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Envoy Medical Reports on First Quarter 2025 Results

    5/1/25 4:30:00 PM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email

    Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear Implant

    White Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.

    Financial and Corporate Highlights for First Quarter and to date:

    • Secured additional $10 Million in funding to advance Pivotal Clinical Trial.

    • Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.

    • Activated (i.e., turned on) six of 10 participants with remaining four participants due to be activated in May. Additionally, two participants completed 1-Month Follow-Up visits.

    • No reports of Serious Adverse Events or Unanticipated Adverse Device Effects.

    • Thus far, activations and follow-up visits have been reported to be within expectations of "typical" or "normal" cochlear implant activations and 1-month follow-up visits over a similar timeframe.

    • Modifications and mitigations put in place between Early Feasibility Study and Pivotal Clinical Trial appear to address previously discussed electrical system noise.

    Brent Lucas, CEO of Envoy Medical commented: "We could not be more pleased with the positive progress of our pivotal clinical study and the reported excitement from the investigational sites. Enrollment of the first 10 patients happened quickly and efficiently, and we believe it is yet another indication that, if given the choice, a meaningful percentage of patients who are candidates for cochlear implants will be drawn to a fully implanted solution that uses the ear to pick up sound instead of a microphone, does not have an implanted magnet in the head, and has multiple days of battery life with typical use. We designed our fully implanted Acclaim cochlear implant with patient's quality of life and preferences in mind, and we are thrilled to see anecdotal reports coming back that people want what our device is designed to offer. Personally, I'm extremely excited about Envoy Medical's future and our position in the hearing industry."

    Financial Results for the Quarter Ended March 31, 2025

    Net revenues decreased $13 thousand for the three months ended March 31, 2025, compared to the three months ended March 31, 2024, primarily due to the decrease in the number of Battery replacement sales due to supply chain limitations. Cost of goods sold increased $73 thousand for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase is primarily due to an increase in headcount in preparation of production growth of the Esteem FI-AMEI product, new supplier expenses and an adjustment to the inventory reserve.

    R&D expenses increased $400 thousand for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase is primarily due to an increase in headcount and contractors in our engineering and clinical departments for the three months ended March 31, 2025, as we increased headcount across our clinical and cochlear departments in preparation for our pivotal clinical study for the Acclaim CI. The Company incurred additional expenses related to the pivotal clinical study in the form of initial site start-up costs, parts and supplies, and data capturing platform.

    Sales and marketing expenses increased $33 thousand for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The increase is primarily due to increased headcount, travel, and the addition of a patient engagement program, partially offset by the reduction of legal and professional fees to secure insurance reimbursement for the Esteem FI-AMEI product.

    General and administrative expenses decreased $284 thousand for the three months ended March 31, 2025, compared to the three months ended March 31, 2024. The decrease is primarily due to reduced legal fees and professional service costs in 2025 compared to 2024, partially offset by an increase in headcount and miscellaneous administrative expenses.

    As of March 31, 2025 cash and cash equivalents were approximately $5.3 million.

    About the Fully Implanted Acclaim® Cochlear Implant

    We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.

    The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.

    The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.

    CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

    About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)

    The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.

    *Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.

    Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.

    Additional Information and Where to Find It

    Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operational improvements and capital investments; the timing and results of IRB approvals, site documents, logistics or activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any institution or healthcare professionals in such trials; the Acclaim CI being the first to market fully implanted cochlear implant; the safety, performance, and market acceptance of the Acclaim CI; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.

    ###

    Investor Relations:
    Envoy Medical Investor Relations
    [email protected]

    Media Contact:
    [email protected]

    ENVOY MEDICAL, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
    (In thousands, except share and per share amounts)


    March 31,
    2025
     December 31, 
    2024

    (Unaudited) 

    Assets

     

    Current assets:

     

    Cash$5,312
     $5,483
    Accounts receivable, net
    42
     
    38
    Other receivable
    23
     
    780
    Inventories
    1,657
     
    1,708
    Prepaid expenses and other current assets
    1,278
     
    1,375
    Total current assets
    8,312
     
    9,384
    Property and equipment, net
    1,220
     
    1,275
    Operating lease right-of-use asset (related party)
    853
     
    879
    Total assets$10,385
     $11,538


     
     
     
    Liabilities and stockholders' deficit
     
     
     
    Current liabilities:
     
     
     
    Accounts payable$1,662
     $1,652
    Accrued expenses
    5,057
     
    4,416
    Other current liabilities
    415
     
    573
    Forward purchase agreement warrant liability
    51
     
    472
    Product warranty liability, current portion
    265
     
    282
    Operating lease liability, current portion (related party)
    145
     
    143
    Total current liabilities
    7,595
     
    7,538
    Term loans payable (related party)
    23,106
     
    18,716
    Product warranty liability, net of current portion
    1,771
     
    1,771
    Operating lease liability, net of current portion (related party)
    778
     
    802
    Publicly traded warrant liability
    468
     
    662
    Other liability
    891
     
    891
    Total liabilities
    34,609
     
    30,380


     
     
     
    Commitments and contingencies (see Note 14)
     
     
     


     
     
     
    Stockholders' deficit
     
     
     
    Series A Preferred Stock, $0.0001 par value; 100,000,000 shares authorized and 10,000,000 shares designated as of March 31, 2025 and December 31, 2024; 4,126,667 shares issued and outstanding as of March 31, 2025 and December 31, 2024
    -
     
    -
    Class A Common Stock, $0.0001 par value; 400,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 21,326,609 shares issued and outstanding as of March 31, 2025 and December 31, 2024
    2
     
    2
    Additional paid-in capital
    266,861
     
    266,013
    Accumulated deficit
    (290,970) 
    (284,734)
    Accumulated other comprehensive loss
    (117) 
    (123)
    Total stockholders' deficit
    (24,224) 
    (18,842)
    Total liabilities and stockholders' deficit$10,385
     $11,538

     

    ENVOY MEDICAL, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
    (In thousands, except share and per share amounts)


    Three Months Ended 
    March 31,

    2025 2024
    Net revenues$46
     $59
    Costs and operating expenses:
     
     
     
    Cost of goods sold
    226
     
    153
    Research and development
    2,748
     
    2,360
    Sales and marketing
    358
     
    325
    General and administrative
    1,821
     
    2,105
    Total costs and operating expenses
    5,153
     
    4,943
    Operating loss
    (5,107) 
    (4,884)
    Other income (expense):
     
     
     
    Change in fair value of forward purchase agreement put option liability
    -
     
    103
    Change in fair value of forward purchase agreement warrant liability
    421
     
    (262)
    Change in fair value of publicly traded warrant liability
    194
     
    (1,177)
    Interest expense, related party
    (495) 
    (36)
    Other expense, net
    (11) 
    (14)
    Total other income (expense), net
    109
     
    (1,386)
    Net loss
    (4,998) 
    (6,270)


     
     
     
    Cumulative preferred dividends
    (1,238) 
    (1,365)


     
     
     
    Net loss attributable to common stockholders, basic and diluted$(6,236) $(7,635)
    Net loss per share attributable to common stockholders, basic and diluted$(0.29) $(0.41)
    Weighted-average Class A Common Stock outstanding, basic and diluted
    21,326,609
     
    18,599,982
    Other comprehensive income (loss):
     
     
     
    Foreign currency translation adjustment
    6
     
    (1)
    Other comprehensive income (loss)
    6
     
    (1)
    Comprehensive loss$(4,992) $(6,271)

     

    ENVOY MEDICAL, INC.
    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
    (In thousands)


    Three Months Ended 
    March 31,

    2025 2024
    Cash flows from operating activities

     

    Net loss$(4,998) $(6,270)
    Adjustments to reconcile net loss to net cash used in operating activities:
     
     
     
    Depreciation
    61
     
    34
    Interest expense and amortization of debt discount on term loans payable (related party)
    495
     
    -
    Amortization of prepaid insurance
    247
     
    270
    Stock-based compensation
    160
     
    123
    Change in fair value of publicly traded warrant liability
    (194) 
    1,177
    Change in fair value of forward purchase agreement warrant liability
    (421) 
    262
    Change in fair value of forward purchase agreement put option liability
    -
     
    (103)
    Change in operating lease right-of-use asset (related party)
    26
     
    31
    Change in inventory reserve
    (23) 
    89
    Changes in operating assets and liabilities:
     
     
     
    Accounts receivable, net
    (4) 
    (119)
    Other receivable
    757
     
    144
    Inventories
    74
     
    (140)
    Prepaid expenses and other current assets
    (75) 
    (56)
    Accounts payable
    10
     
    (641)
    Operating lease liability (related party)
    (22) 
    (27)
    Accrued expenses
    199
     
    (357)
    Product warranty liability
    (17) 
    (6)
    Other liability
    -
     
    -
    Net cash used in operating activities
    (3,725) 
    (5,589)


     
     
     
    Cash flows from investing activities
     
     
     
    Purchases of property and equipment
    (6) 
    -
    Deposits on equipment not yet placed in service
    -
     
    (109)
    Net cash used in investing activities
    (6) 
    (109)


     
     
     
    Cash flows from financing activities
     
     
     
    Payments on insurance financing loans
    (233) 
    (257)
    Proceeds from the issuance of term loans (related party)
    5,000
     
    5,000
    Dividends paid to stockholders of Series A Preferred Stock
    (1,213) 
    -
    Proceeds from the sale of Common Stock associated with forward purchase agreement, net of transaction costs
    -
     
    1,683
    Net cash provided by financing activities
    3,554
     
    6,426


     
     
     
    Effect of exchange rate changes on cash
    6
     
    (1)
    Net (decrease) increase in cash
    (171) 
    727
    Cash, beginning of period
    5,483
     
    4,218
    Cash, end of period$5,312
     $4,945


     
     
     
    Supplemental disclosures of cash flow information:
     
     
     
    Cash paid for interest$13
     $14
    Non-cash investing and financing activities:
     
     
     
    Accrued and unpaid dividends on Series A Preferred Stock$25
     $1,365
    Financing of prepaid insurance$75
     $65
    Warrants issued with term loans (related party)$688
     $-

     

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250488

    Get the next $COCH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial

      White Bear Lake, Minnesota--(Newsfile Corp. - May 13, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announces achieving the important milestone of successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. Brent Lucas, CEO of Envoy Medical commented: "We are excited to report the positive and meaningful progress of our pivotal clinical trial, which is currently on track and moving along as anticipated. We are optimistic we will be able to expand the study

      5/13/25 9:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports on First Quarter 2025 Results

      Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

      5/1/25 4:30:00 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • EdgarAgents Debuts EA34 Plugin at Centri Capital Conference to Simplify and Expedite Financial Filing Process for Mid-to-Microcap Companies

      NEW YORK, April 22, 2025 (GLOBE NEWSWIRE) -- EdgarAgents (EA), a leading provider of simplified and efficient solutions that expedite U.S. Securities and Exchange Commission (SEC®) compliance filings, announces today the availability of EA34 Plugin, the company's newest user-centered technology-enabled solution. EA34 Plugin officially launches at the Centri Capital Conference in New York City at Nasdaq Global Headquarters. Powered by the latest inline eXtensible Business Reporting Language (iXBRL) — a global standard to share financial and business data electronically — and EDGAR® technology, EA34 Plugin was tailor-made as a "hybrid-service" financial content management collaboration pla

      4/22/25 6:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      5/27/25 6:34:31 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Taylor Glen A

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      3/13/25 4:06:56 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Kantor Susan acquired 34,705 shares, increasing direct ownership by 80% to 77,887 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      12/26/24 5:52:27 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    See more
    • Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

      WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

      6/11/24 8:00:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical to Host Fireside Chat Event December 7

      Analyst Hosted Event to Feature Comprehensive Discussion of Envoy Medical's Products, Interviews with Two Study Investigators and Key Opinion Leaders in Cochlear Implants WHITE BEAR LAKE, Minnesota, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ: "COCH"), a revolutionary hearing health company focused on fully implanted hearing systems, today announced that it will host a fireside chat event on Thursday December 7, 2023 beginning at noon Central Time. The event will be hosted by a covering research analyst and feature interactive Q&A with Brent T. Lucas, Chief Executive Officer, and David R. Wells, Chief Financial Officer. Additionally, the Company

      12/4/23 8:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brynelsen Charles bought $82,403 worth of shares (50,000 units at $1.65) (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      5/27/25 6:34:31 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $5,699 worth of shares (2,500 units at $2.28), increasing direct ownership by 50% to 7,500 units (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      11/22/24 4:32:31 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Director Patel Mona Chetan bought $16,520 worth of shares (5,000 units at $3.30) (SEC Form 4)

      4 - Envoy Medical, Inc. (0001840877) (Issuer)

      9/11/24 4:50:47 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    SEC Filings

    See more
    • Envoy Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      5/19/25 8:52:08 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Envoy Medical Inc.

      SCHEDULE 13G/A - Envoy Medical, Inc. (0001840877) (Subject)

      5/15/25 8:59:37 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Envoy Medical, Inc. (0001840877) (Filer)

      5/1/25 4:44:23 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

      Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

      6/24/24 7:29:10 AM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/14/24 8:49:34 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Envoy Medical Inc.

      SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

      11/13/24 4:40:10 PM ET
      $COCH
      Industrial Specialties
      Health Care

    $COCH
    Financials

    Live finance-specific insights

    See more
    • Envoy Medical Reports on First Quarter 2025 Results

      Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

      5/1/25 4:30:00 PM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

      Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

      3/31/25 9:15:00 AM ET
      $COCH
      Industrial Specialties
      Health Care
    • Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events

      WHITE BEAR LAKE, Minn., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH), a revolutionary hearing health company focused on fully implanted hearing devices, today announces its corporate and financial results for the third quarter ended September 30, 2024, as well as other subsequent events. "The progress and accomplishments of late have been extremely important to Envoy Medical as they have set the stage for us to demonstrate the value of fully implanted hearing devices. First, we have received FDA's approval to start our pivotal trial of the Acclaim® fully implanted cochlear implant ("Acclaim CI"). Second, we continue to make tremendous

      11/14/24 8:38:22 AM ET
      $COCH
      Industrial Specialties
      Health Care